Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission. Issue 7 (2nd July 2016)

• Record Type: Journal Article
• Authors: Mannis, Gabriel N.; Martin, Thomas G.; Damon, Lloyd E.; Logan, Aaron C.; Olin, Rebecca L.; Flanders, Michael D.; Ai, Weiyun Z.; Gaensler, Karin M. L.; Kaplan, Lawrence D.; Sayre, Peter H.; Smith, Catherine C.; Wolf, Jeffrey L.; Andreadis, Charalambos
• Is Part Of: Leukemia & lymphoma. Volume 57:Issue 7(2016:Jul.)
• Page Start: 1560
• Page End: 1566
• Publication Date: 2016-07-02
• Subjects: Acute myeloid leukemia -- autologous transplantation -- outcomes; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2015.1088646
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: In 2014, autologous hematopoietic cell transplant (autoHCT) was removed from the National Comprehensive Cancer Network guidelines as a recommended treatment for patients with intermediate-risk AML in first complete remission (CR1). We reviewed the outcomes of all patients with intermediate-risk AML treated with autoHCT in CR1 at our institution. Of 334 patients who underwent autoHCT for AML between 1988 and 2013, 133 patients with intermediate-risk AML in CR1 were identified. Cytogenetics were diploid in 97 (73%). With a median follow-up of 4.1 years (range 0.1–17), median overall survival (OS) is 6.7 years; at 5 years post-transplant, 59% of patients remain alive and 43% remain relapse-free. Forty-eight percent of relapsing patients proceeded to salvage alloHCT. Our findings demonstrate that nearly half of patients with intermediate-risk AML in CR1 achieve sustained remissions, and that salvage alloHCT is feasible in those who relapse. AutoHCT therefore remains a reasonable option for intermediate-risk patients with AML in CR1.